Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Get the IL-17F outta here!

Hall AO, Towne JE, Plevy SE.

Nat Immunol. 2018 Jul;19(7):648-650. doi: 10.1038/s41590-018-0141-z. No abstract available.

PMID:
29915294
2.

Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn's Disease.

VanDussen KL, Stojmirović A, Li K, Liu TC, Kimes PK, Muegge BD, Simpson KF, Ciorba MA, Perrigoue JG, Friedman JR, Towne JE, Head RD, Stappenbeck TS.

Gastroenterology. 2018 Sep;155(3):815-828. doi: 10.1053/j.gastro.2018.05.028. Epub 2018 May 18.

PMID:
29782846
3.

Regulation and function of interleukin-36 cytokines.

Bassoy EY, Towne JE, Gabay C.

Immunol Rev. 2018 Jan;281(1):169-178. doi: 10.1111/imr.12610. Review.

PMID:
29247994
4.

Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses.

D'Souza WN, Douangpanya J, Mu S, Jaeckel P, Zhang M, Maxwell JR, Rottman JB, Labitzke K, Willee A, Beckmann H, Wang Y, Li Y, Schwandner R, Johnston JA, Towne JE, Hsu H.

PLoS One. 2017 Jul 20;12(7):e0180190. doi: 10.1371/journal.pone.0180190. eCollection 2017.

5.

Mutation in IL36RN impairs the processing and regulatory function of the interleukin-36-receptor antagonist and is associated with DITRA syndrome.

Bal E, Lim AC, Shen M, Douangpanya J, Madrange M, Gazah R, Tauber M, Beghdadi W, Casanova JL, Bourrat E, Bachelez H, Towne JE, Smahi A.

Exp Dermatol. 2017 Jun 11. doi: 10.1111/exd.13387. [Epub ahead of print]

PMID:
28603914
6.

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases.

Nirula A, Nilsen J, Klekotka P, Kricorian G, Erondu N, Towne JE, Russell CB, Martin DA, Budelsky AL.

Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii43-ii55. Review.

PMID:
27856660
7.

Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines.

Dietrich D, Martin P, Flacher V, Sun Y, Jarrossay D, Brembilla N, Mueller C, Arnett HA, Palmer G, Towne J, Gabay C.

Cytokine. 2016 Aug;84:88-98. doi: 10.1016/j.cyto.2016.05.012. Epub 2016 May 31.

PMID:
27259168
8.

Sushi barcoding in the UK: another kettle of fish.

Vandamme SG, Griffiths AM, Taylor SA, Di Muri C, Hankard EA, Towne JA, Watson M, Mariani S.

PeerJ. 2016 Mar 31;4:e1891. doi: 10.7717/peerj.1891. eCollection 2016.

9.

Cutting Edge: IL-36 Receptor Promotes Resolution of Intestinal Damage.

Medina-Contreras O, Harusato A, Nishio H, Flannigan KL, Ngo V, Leoni G, Neumann PA, Geem D, Lili LN, Ramadas RA, Chassaing B, Gewirtz AT, Kohlmeier JE, Parkos CA, Towne JE, Nusrat A, Denning TL.

J Immunol. 2016 Jan 1;196(1):34-8. doi: 10.4049/jimmunol.1501312. Epub 2015 Nov 20.

10.

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation.

Maxwell JR, Zhang Y, Brown WA, Smith CL, Byrne FR, Fiorino M, Stevens E, Bigler J, Davis JA, Rottman JB, Budelsky AL, Symons A, Towne JE.

Immunity. 2015 Oct 20;43(4):739-50. doi: 10.1016/j.immuni.2015.08.019. Epub 2015 Sep 29.

11.

Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions.

Gabay C, Towne JE.

J Leukoc Biol. 2015 Apr;97(4):645-52. doi: 10.1189/jlb.3RI1014-495R. Epub 2015 Feb 11. Review.

PMID:
25673295
12.

Elimination of Pasteurella pneumotropica from a mouse barrier facility by using a modified enrofloxacin treatment regimen.

Towne JW, Wagner AM, Griffin KJ, Buntzman AS, Frelinger JA, Besselsen DG.

J Am Assoc Lab Anim Sci. 2014 Sep;53(5):517-22.

13.

Preclinical development of AMG 139, a human antibody specifically targeting IL-23.

Köck K, Pan WJ, Gow JM, Horner MJ, Gibbs JP, Colbert A, Goletz TJ, Newhall KJ, Rees WA, Sun Y, Zhang Y, O'Neill JC, Umble-Romero AN, Prokop SP, Krill CD, Som L, Buntich SA, Trimble MW, Tsuji WH, Towne JE.

Br J Pharmacol. 2015 Jan;172(1):159-72. doi: 10.1111/bph.12904. Epub 2014 Dec 15.

14.

Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.

Derer A, Groetsch B, Harre U, Böhm C, Towne J, Schett G, Frey S, Hueber AJ.

PLoS One. 2014 Aug 11;9(8):e101954. doi: 10.1371/journal.pone.0101954. eCollection 2014.

15.

Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.

von Scheidt B, Leung PS, Yong MC, Zhang Y, Towne JE, Smyth MJ, Teng MW.

Cancer Res. 2014 May 1;74(9):2412-21. doi: 10.1158/0008-5472.CAN-13-1646. Epub 2014 Feb 20.

16.

ALK+ Anaplastic Large Cell Lymphoma With Bladder Involvement Presenting as Fever of Unknown Origin: A Case Report and Literature Review.

Lawrenz J, Tomal J, Towne J, Johnson B, Rieger B.

World J Oncol. 2013 Apr;4(2):95-101. doi: 10.4021/wjon644w. Epub 2013 May 6.

17.

The severity of experimental arthritis is independent of IL-36 receptor signaling.

Lamacchia C, Palmer G, Rodriguez E, Martin P, Vigne S, Seemayer CA, Talabot-Ayer D, Towne JE, Gabay C.

Arthritis Res Ther. 2013 Mar 1;15(2):R38. doi: 10.1186/ar4192.

18.

The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

Lowes MA, Russell CB, Martin DA, Towne JE, Krueger JG.

Trends Immunol. 2013 Apr;34(4):174-81. doi: 10.1016/j.it.2012.11.005. Epub 2013 Jan 3. Review.

19.

Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state.

Teng MW, Vesely MD, Duret H, McLaughlin N, Towne JE, Schreiber RD, Smyth MJ.

Cancer Res. 2012 Aug 15;72(16):3987-96. doi: 10.1158/0008-5472.CAN-12-1337. Epub 2012 Aug 6.

20.

The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.

Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB.

J Invest Dermatol. 2013 Jan;133(1):17-26. doi: 10.1038/jid.2012.194. Epub 2012 Jun 7. Review.

21.

IL-36 in psoriasis.

Towne JE, Sims JE.

Curr Opin Pharmacol. 2012 Aug;12(4):486-90. doi: 10.1016/j.coph.2012.02.009. Epub 2012 Mar 5. Review.

PMID:
22398321
22.

Are Th17 cells in the gut pathogenic or protective?

Symons A, Budelsky AL, Towne JE.

Mucosal Immunol. 2012 Jan;5(1):4-6. doi: 10.1038/mi.2011.51. Epub 2011 Nov 9.

PMID:
22071661
23.

Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36α, IL-36β, and IL-36γ) or antagonist (IL-36Ra) activity.

Towne JE, Renshaw BR, Douangpanya J, Lipsky BP, Shen M, Gabel CA, Sims JE.

J Biol Chem. 2011 Dec 9;286(49):42594-602. doi: 10.1074/jbc.M111.267922. Epub 2011 Sep 29.

24.

Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis.

Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei XY, Fraitag S, Zribi J, Bal E, Cluzeau C, Chrabieh M, Towne JE, Douangpanya J, Pons C, Mansour S, Serre V, Makni H, Mahfoudh N, Fakhfakh F, Bodemer C, Feingold J, Hadj-Rabia S, Favre M, Genin E, Sahbatou M, Munnich A, Casanova JL, Sims JE, Turki H, Bachelez H, Smahi A.

N Engl J Med. 2011 Aug 18;365(7):620-8. doi: 10.1056/NEJMoa1013068.

25.

Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.

Teng MW, von Scheidt B, Duret H, Towne JE, Smyth MJ.

Cancer Res. 2011 Mar 15;71(6):2077-86. doi: 10.1158/0008-5472.CAN-10-3994. Epub 2011 Jan 31.

26.

Moving lean beyond the emergency department.

Towne J.

Hosp Health Netw. 2010 Nov;84(11):54. No abstract available.

PMID:
21162406
27.

Lean transformations. Planning a 'lean' health care makeover.

Towne J.

Health Facil Manage. 2010 Oct;23(10):51-4. No abstract available.

PMID:
21090224
28.

IL-1RL2 and its ligands contribute to the cytokine network in psoriasis.

Blumberg H, Dinh H, Dean C Jr, Trueblood ES, Bailey K, Shows D, Bhagavathula N, Aslam MN, Varani J, Towne JE, Sims JE.

J Immunol. 2010 Oct 1;185(7):4354-62. doi: 10.4049/jimmunol.1000313. Epub 2010 Sep 10.

29.

Multiple functional groups of varying ratios in metal-organic frameworks.

Deng H, Doonan CJ, Furukawa H, Ferreira RB, Towne J, Knobler CB, Wang B, Yaghi OM.

Science. 2010 Feb 12;327(5967):846-50. doi: 10.1126/science.1181761.

30.

Hospitals in pursuit of excellence.

Towne J.

Hosp Health Netw. 2009 Mar;83(3):50-1. No abstract available.

PMID:
19391432
31.

Teamwork improves care.

Towne J.

Hosp Health Netw. 2009 Jan;83(1):50-1. No abstract available.

PMID:
19266731
32.

The extent of lower extremity occlusive disease predicts short- and long-term patency following endovascular infrainguinal arterial intervention.

Hasanadka R, Brown KR, Rilling WS, Rossi PJ, Hieb RA, Hohenwalter EJ, Seabrook GR, Lewis BD, Towne JB.

Am J Surg. 2008 Nov;196(5):629-33. doi: 10.1016/j.amjsurg.2008.07.010. Epub 2008 Sep 11.

PMID:
18789419
33.

Preoperative shower revisited: can high topical antiseptic levels be achieved on the skin surface before surgical admission?

Edmiston CE Jr, Krepel CJ, Seabrook GR, Lewis BD, Brown KR, Towne JB.

J Am Coll Surg. 2008 Aug;207(2):233-9. doi: 10.1016/j.jamcollsurg.2007.12.054. Epub 2008 May 23.

PMID:
18656052
34.

Guidelines for hospital privileges in vascular and endovascular surgery: recommendations of the Society for Vascular Surgery.

Calligaro KD, Toursarkissian B, Clagett GP, Towne J, Hodgson K, Moneta G, Sidawy AN, Cronenwett JL; Clinical Practice Council, Society for Vascular Surgery.

J Vasc Surg. 2008 Jan;47(1):1-5. Epub 2007 Dec 3.

35.

Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation.

Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D, Weng N, Kanaly ST, Towne JE, Willis CR, Kuechle MK, Sims JE, Peschon JJ.

J Exp Med. 2007 Oct 29;204(11):2603-14. Epub 2007 Oct 1.

36.

Computed tomography angiography to evaluate thoracic outlet neurovascular compression.

Hasanadka R, Towne JB, Seabrook GR, Brown KR, Lewis BD, Foley WD.

Vasc Endovascular Surg. 2007 Aug-Sep;41(4):316-21.

PMID:
17704334
37.

Tissue and fluid penetration of garenoxacin in surgical patients.

Edmiston CE, Krepel CJ, Seabrook GR, Towne JB, Smith TL, Loehrl TA, Wackym PA, Johnson CP, Otterson MF, Gajjar DA, Krishna G.

Surg Infect (Larchmt). 2007 Apr;8(2):179-88.

PMID:
17437363
38.

The evolution of practice and training in vascular surgery.

Towne JB.

Am Surg. 2007 Feb;73(2):152-4. Review. No abstract available.

PMID:
17305292
39.

Primary certification in vascular surgery: what does this really mean?

Towne JB.

Semin Vasc Surg. 2006 Dec;19(4):165-7.

PMID:
17178316
40.

Going 'lean' streamlines processes, empowers staff and enhances care.

Towne J.

Hosp Health Netw. 2006 Oct;80(10):34-5. No abstract available.

PMID:
17111579
41.

Bacterial adherence to surgical sutures: can antibacterial-coated sutures reduce the risk of microbial contamination?

Edmiston CE, Seabrook GR, Goheen MP, Krepel CJ, Johnson CP, Lewis BD, Brown KR, Towne JB.

J Am Coll Surg. 2006 Oct;203(4):481-9. Epub 2006 Aug 22.

PMID:
17000391
42.

Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices.

Edmiston CE Jr, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR, Towne JB.

Am J Surg. 2006 Sep;192(3):344-54.

PMID:
16920429
43.

11 IL-1 family members in inflammatory skin disease.

Sims J, Towne J, Blumberg H.

Ernst Schering Res Found Workshop. 2006;(56):187-91. Review.

PMID:
16329652
44.

Molecular epidemiology of microbial contamination in the operating room environment: Is there a risk for infection?

Edmiston CE Jr, Seabrook GR, Cambria RA, Brown KR, Lewis BD, Sommers JR, Krepel CJ, Wilson PJ, Sinski S, Towne JB.

Surgery. 2005 Oct;138(4):573-9; discussion 579-82.

PMID:
16269284
45.

Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.

Edmiston CE Jr, Krepel CJ, Kehl KS, Seabrook GR, Somberg LB, Almassi GH, Smith TL, Loehrl TA, Brown KR, Lewis BD, Towne JB.

J Antimicrob Chemother. 2005 Nov;56(5):872-8. Epub 2005 Sep 26.

PMID:
16186167
46.

Commentary. Validity of exam assessment of surgical skills EBSQ/VASC pilot study.

Towne JB.

Perspect Vasc Surg Endovasc Ther. 2005 Jun;17(2):175-6. No abstract available.

PMID:
16110390
47.

NHII: Achievable goal or house of cards.

Towne J.

Hosp Health Netw. 2005 Jun;79(6):suppl 7 following 70. No abstract available.

PMID:
16047628
48.

Operative strategies in aortic graft infections: is complete graft excision always necessary?

Hart JP, Eginton MT, Brown KR, Seabrook GR, Lewis BD, Edmiston CE Jr, Towne JB, Cambria RA.

Ann Vasc Surg. 2005 Mar;19(2):154-60.

PMID:
15776307
49.

Information technology ROI. A CEO's Guide to measuring and evaluating IT's financial effectiveness.

Runy LA, Towne J.

Hosp Health Netw. 2005 Feb;79(2):45, 47-50, 2.

PMID:
15770909
50.

Endovascular treatment of abdominal aortic aneurysms.

Towne JB.

Am J Surg. 2005 Feb;189(2):140-9. Review.

PMID:
15720980

Supplemental Content

Support Center